文献速递免疫规划传染病防控与疫情报告

RTS,S/AS01E疟疾疫苗在非洲儿童中诱导针对CSP及疫苗无关抗原的IgA应答

RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial.
PubMed 文献 · Vaccine · 2020-12-25

结果显示疫苗诱导针对所有CSP构件的IgA升高1.2-2倍,且13/16种疫苗无关疟原虫抗原IgA也升高,但探索性分析未发现IgA与保护性显著相关。

要点

  • RTS,S/AS01E诱导针对CSP及多种疫苗无关疟原虫抗原的血清IgA应答。
  • 疫苗诱导的IgA水平在高传播强度站点接种前更高。
  • 探索性分析未发现IgA与保护性存在统计学显著关联。

核心结论

  • RTS,S/AS01E在外周血中诱导针对CSP疫苗抗原和其他疫苗无关疟原虫抗原的IgA应答,类似此前观察到的IgG应答。
  • 需进一步研究疫苗诱导IgA对效力的潜在贡献及其与保护性IgG的协同或拮抗作用。

研究设计与样本

  • 纳入两个疟疾传播强度不同的站点,包括临床疟疾病例和对照。
  • 初级免疫后1个月采用定量悬浮阵列 assay 检测针对CSP不同构件及16种疫苗无关恶性疟原虫抗原的IgA。

主要发现

  • RTS,S接种诱导针对所有CSP构件的血清/血浆IgA抗体水平升高1.2至2倍,对照疫苗未观察到此现象。
  • 针对16种疫苗无关恶性疟原虫抗原中的13种,接种后IgA应答也升高,且RTS,S受种者水平高于对照。
  • 接种前针对疟疾抗原的IgA水平在高传播强度站点高于低传播强度站点。
  • 探索性分析未发现IgA与保护性之间存在统计学显著关联。

临床怎么用

  • 当前RTS,S/AS01E免疫评价仍以IgG抗体为主,IgA检测尚未成为常规评估指标。
  • 疫苗诱导的IgA应答与保护性关系不明确,临床暂不据此调整接种策略。

局限性

  • 探索性分析未发现IgA与保护的显著关联,样本量有限。
  • 仅检测初级免疫后1个月的外周血IgA,未评估长期动态。
  • IgA与IgG的协同或拮抗作用未在本研究中阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The evaluation of immune responses to RTS,S/AS01 has traditionally focused on immunoglobulin (Ig) G antibodies that are only moderately associated with protection. The role of other antibody isotypes that could also contribute to vaccine efficacy remains unclear. Here we investigated whether RTS,S/AS01E elicits antigen-specific serum IgA antibodies to the vaccine and other malaria antigens, and we explored their association with protection. METHODS: Ninety-five children (age 5-17 months old at first vaccination) from the RTS,S/AS01E phase 3 clinical trial who received 3 doses of RTS,S/AS01E or a comparator vaccine were selected for IgA quantification 1 month post primary immunization. Two sites with different malaria transmission intensities (MTI) and clinical malaria cases and controls, were included. Measurements of IgA against different constructs of the circumsporozoite protein (CSP) vaccine antigen and 16 vaccine-unrelated Plasmodium falciparum antigens were performed using a quantitative suspension array assay. RESULTS: RTS,S vaccination induced a 1.2 to 2-fold increase in levels of serum/plasma IgA antibodies to all CSP constructs, which was not observed upon immunization with a comparator vaccine. The IgA response against 13 out of 16 vaccine-unrelated P. falciparum antigens also increased after vaccination, and levels were higher in recipients of RTS,S than in comparators. IgA levels to malaria antigens before vaccination were more elevated in the high MTI than the low MTI site. No statistically significant association of IgA with protection was found in exploratory analyses. CONCLUSIONS: RTS,S/AS01E induces IgA responses in peripheral blood against CSP vaccine antigens and other P. falciparum vaccine-unrelated antigens, similar to what we previously showed for IgG responses. Collectively, data warrant further investigation of the potential contribution of vaccine-induced IgA responses to efficacy and any possible interplay, either synergistic or antagonistic, with protective IgG, as identifying mediators of protection by RTS,S/AS01E immunization is necessary for the design of improved second-generation vaccines. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT008666191.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Suau R, Vidal M, Aguilar R, et al. RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial. Vaccine. 2020. PMID: 33358704. doi:10.1016/j.vaccine.2020.12.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。